Received Jun 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Flu-like symptoms; did not received 2nd dose yet; This non-serious case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 51-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. In JUL-2024, the patient received the 1st dose of Shingrix. On an unknown date, the patient did not receive the 2nd dose of Shingrix. In JUL-2024, 1 day after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced influenza-like symptoms (Verbatim: Flu-like symptoms). On an unknown date, the patient experienced incomplete course of vaccination (Verbatim: did not received 2nd dose yet). In JUL-2024, the outcome of the influenza-like symptoms was resolved. The outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the influenza-like symptoms to be related to Shingrix. It was unknown if the company considered the influenza-like symptoms to be related to Shingrix. Additional Information: GSK receipt date: 25-JUN-2025 The patient received her first Shingrix dose and one day after vaccination she developed unspecified flu-like symptoms and missed one day of work (AE, recovered). She has not yet received the second dose but plans to (adverse event: inappropriate schedule of vaccine). Nothing else was reported. This report was filed with limited detail as the patient declined to provide her mailing address or answer questions regarding the adverse event report. Till the time of reporting, the patient did not receive second dose of Shingrix, which led to incomplete course of vaccination.